Figure 1.
Ibrutinib therapy is associated with a reduction in PDL1 expression on the surface of CD19+ B cells.

Ibrutinib therapy is associated with a reduction in PDL1 expression on the surface of CD19+ B cells.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal